Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.

Kohei KotaniMasaru EnomotoSawako Uchida-KobayashiAkihiro TamoriYoshimi Yukawa-MutoNaoshi OdagiriHiroyuki MotoyamaRitsuzo KozukaEtsushi KawamuraAtsushi HagiharaHideki FujiiKen KageyamaAkira YamamotoAtsushi YoshidaShigeaki HigashiyamaJoji KawabeNorifumi Kawada

Published in: Journal of gastroenterology (2023)

Achieving SVR24 with SOF/VEL treatment in patients with decompensated hepatitis C-related cirrhosis can be expected to improve hepatocyte function and portal hypertension on short-term follow-up.

Keyphrases

blood pressure
heart failure
hepatitis c virus
liver failure
type diabetes
metabolic syndrome
insulin resistance
atrial fibrillation
weight loss
hepatitis c virus infection
glycemic control